⌘K

Login Start Free

Home/Filings/4/0001209191-22-049015

4//SEC Filing

AULIN SHERRY 4

Accession 0001209191-22-049015

CIK 0001582313other

View on SEC.gov Company Profile

Filed

Sep 6, 8:00 PM ET

Accepted

Sep 7, 4:26 PM ET

Size

25.4 KB

Accession

0001209191-22-049015

Insider Transaction Report

Form 4

Period: 2022-09-02

Xenon Pharmaceuticals Inc.XENE

Chief Financial Officer

Transactions

Sale
Common Shares
2022-09-02$39.57/sh−15,355$607,597→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-09-02−813→ 0 total
Exercise: $8.40Exp: 2027-03-12→ Common Shares (813 underlying)
Exercise/Conversion
Common Shares
2022-09-02$9.44/sh+9,000$84,960→ 9,000 total
Tax Payment
Common Shares
2022-09-02$39.53/sh−3,293$130,172→ 15,355 total
Exercise/Conversion
Common Shares
2022-09-02$3.10/sh+2,292$7,105→ 12,137 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-09-02−32→ 0 total
Exercise: $7.49Exp: 2026-03-10→ Common Shares (32 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-09-02−6,511→ 0 total
Exercise: $4.75Exp: 2028-03-11→ Common Shares (6,511 underlying)
Exercise/Conversion
Common Shares
2022-09-02$7.49/sh+32$240→ 9,032 total
Exercise/Conversion
Common Shares
2022-09-02$8.40/sh+813$6,829→ 9,845 total
Exercise/Conversion
Common Shares
2022-09-02$4.75/sh+6,511$30,927→ 18,648 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-09-02−9,000→ 0 total
Exercise: $9.44Exp: 2029-09-15→ Common Shares (9,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-09-02−2,292→ 0 total
Exercise: $3.10Exp: 2027-10-22→ Common Shares (2,292 underlying)

Footnotes (3)

[F1]Represents the closing price of the Company's common shares on September 1, 2022 for purposes of net settlement calculations.
[F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
[F3]The shares subject to the option are fully vested and exercisable.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

Entity typeother

Related Parties

1

filerCIK 0001862144

Filing Metadata

Form type: 4
Filed: Sep 6, 8:00 PM ET
Accepted: Sep 7, 4:26 PM ET
Size: 25.4 KB

View on SEC.gov